Chronic obstructive pulmonary disease - roflumilast (TA244)
Fast, easy summary view of NICE guidance on 'chronic obstructive pulmonary disease'
NICE recommends roflumilast for people with severe COPD only if they are taking part in a research study (clinical trial) that is investigating using roflumilast at the same time as a bronchodilator (a type of inhaled drug).
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.
NICE recommended that roflumilast should be used only as part of a research study because at the moment there is not enough evidence about how well it works or about the best way to use it to recommend it for use in the NHS.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: chronic obstructive pulmonary disease
- None found
This page was last updated: 01 February 2013
- Web format
- Full Guidance (PDF)
- TA244 Roflumilast ar gyfer clefyd rhwystrol cronig yr ysgyfaint difrifol: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.